VEGFA and renal cell carcinoma: Indeed, targeting the VEGF/mTOR pathway with a combination of mTOR (temsirolimus) and an antibody directed against VEGF (bevacizumab) is being evaluated in a Phase II clinical trial for patients with RCC (Gordan et al., 2008).